How to get ADHD medication in Oregon and Idaho: the 2026 telehealth rules

If you live in Oregon or Idaho and want ADHD medication managed over telehealth, the rules in 2026 are workable but specific. The DEA extended pandemic-era telehealth flexibilities for controlled substances through December 31, 2026 (Federal Register, December 31, 2025 Fourth Temporary Extension). That means a psychiatric clinician can evaluate you by live video and, if appropriate, prescribe Schedule II medications — including stimulants like Adderall, Vyvanse, and methylphenidate — without an in-person visit first.

This post is a practical orientation for prospective patients in Oregon and Idaho. Not legal advice. Rules change; verify anything time-sensitive with your clinician before you rely on it.

Key Takeaways

• ADHD stimulants (Schedule II) can be prescribed via video telehealth in Oregon and Idaho through December 31, 2026 under DEA's fourth temporary extension.
• The visit must be live audio and video — not audio-only, not chat.
• Your clinician still has to run a PDMP check, verify your identity and location, screen for controlled-substance history, and document a legitimate medical purpose.
• State scope-of-practice rules apply. PMHNPs (like me) with DEA registration in Oregon and Idaho can prescribe stimulants directly, no supervising physician required.
• If the DEA does not extend the rule again or finalizes the pending Special Registration framework, the path may change in 2027. Have a plan for continuity.

What the current rule actually says

The DEA's Fourth Temporary Extension keeps three things in place through the end of 2026:

• A DEA-registered clinician can prescribe any Schedule II–V controlled substance via telehealth without an in-person exam.
• The prescription must follow a live audio-video encounter.
• The clinician must comply with the applicable state law where the patient is located.

Requirements the clinician must meet on every controlled-substance visit (Lengea Law telehealth summary):

• Legitimate medical purpose established through examination
• Live audio-video (not audio-only, except in narrow buprenorphine cases)
• State licensure in the patient's state
• DEA registration valid for that state
• PDMP (prescription drug monitoring program) check
• Complete clinical documentation

Buprenorphine has its own permanent rule — up to 6 months of telehealth (audio-only allowed) before an in-person visit is required. That does not apply to stimulants.

The DEA published a proposed Special Registration framework in January 2025 that would create a longer-term telehealth prescribing pathway with additional oversight (AMA advocacy update). As of mid-2026, it is not finalized. The extension through December 31, 2026 is what you should count on.

Oregon specifics

Oregon telehealth is governed by ORS 677.050–677.097 and the Oregon Medical Board's telemedicine guidance (Oregon Medical Board). For nurse practitioners, the Oregon State Board of Nursing applies the same telemedicine standard: you must be licensed in Oregon, provide the same standard of care as in-person, and comply with DEA rules.

What that means for you as an Oregon patient:

• The clinician must be Oregon-licensed. My PMHNP-BC license is active in Oregon.
• Video visits count as full clinical encounters for both the initial evaluation and follow-ups.
• PDMP query is required before any controlled substance prescription is sent. Oregon uses the Oregon Prescription Drug Monitoring Program (PDMP).
• Commercial insurance in Oregon (including PacificSource commercial plans) covers telehealth psychiatry on the same terms as in-person. Embrace Psychiatry is currently a self-pay practice ($400 intake / $200 follow-up); we can provide a superbill for out-of-network reimbursement.
• No Medicare or Medicaid — self-pay only.
• If you have a history of substance use, prior stimulant misuse, or a diagnosis that raises red flags on PDMP, we may ask you to establish care with a local prescriber who can see you in person before starting Schedule II medication.

Idaho specifics

Idaho telehealth is governed by the Idaho Telehealth Access Act (Idaho Code Chapter 57, Title 54). The Idaho Board of Nursing recognizes video telehealth as equivalent to in-person for scope-of-practice purposes.

What that means for Idaho patients:

• Idaho PMHNP-BC license required — mine is active.
• Video is sufficient for initial evaluation and follow-up.
• PDMP check via Idaho's PMP is required before any controlled substance is prescribed.
• Idaho is a full practice authority state for nurse practitioners — no collaborative agreement or supervising physician required.
• Same self-pay structure: $400 intake, $200 follow-up, superbill available.

What the first visit looks like

A first visit for adult ADHD evaluation runs about 60 minutes over video. Expect:

• Verification of identity and physical location (required for controlled substance prescribing)
• Full psychiatric history: developmental, medical, psychiatric, substance use, family
• Symptom review using validated screeners — usually ASRS v1.1, sometimes DIVA-5
• Review of prior records if you have them (school reports, prior evaluations, prior prescriptions)
• Discussion of risks, benefits, and alternatives — stimulant vs non-stimulant, medication vs behavioral, watch-and-wait
• PDMP check before any prescription is sent
• A written plan sent through the patient portal same day

If we prescribe a stimulant at the first visit, the medication goes to the pharmacy of your choice. First-fill of a Schedule II cannot be sent to certain out-of-state mail-order pharmacies, so we usually use your local pharmacy.

Benefits and Limits

Benefits of telehealth ADHD care:

• No commute, no waiting room, no time off work
• Same clinician every visit — no handoffs
• Faster appointment availability than most in-person practices
• Full parity with in-person visits under current DEA and state rules

Limits:

• No physical exam. If you need vitals checked (blood pressure on stimulants, for example), you self-report or use a home cuff.
• No in-office lab draws. If we need labs (rare for straightforward ADHD, common if we're ruling out thyroid, anemia, or metabolic causes of symptoms), we send an order to a local Quest or LabCorp.
• The DEA rule is a temporary extension. If Congress or DEA does not extend again past December 31, 2026, you may need an in-person visit to continue a Schedule II prescription. Plan for that.
• If you're in acute psychiatric crisis, telehealth is the wrong tool. Local ER or crisis line.

Risks, Side Effects, or When to Reach Out

Stimulants and non-stimulants both have real side effects. Common issues to expect:

• Stimulants (amphetamine, methylphenidate classes): decreased appetite, insomnia, dry mouth, mild blood pressure and heart rate elevation, irritability especially at wear-off
• Non-stimulants (atomoxetine, guanfacine, clonidine): fatigue, GI upset, blood pressure changes (down for guanfacine/clonidine, occasionally up for atomoxetine), mood changes

Reach out through Spruce or the patient portal promptly if you experience:

• Resting heart rate persistently above 100 bpm
• New or worsening chest pain, palpitations, or shortness of breath
• New or worsening anxiety, depression, or suicidal thinking
• Sleep completely destroyed (not just delayed by an hour or two)
• Any allergic reaction

Rare but serious: cardiac events in patients with undiagnosed structural heart disease, psychiatric side effects including psychosis (uncommon), and misuse/diversion. Screening at intake reduces but does not eliminate these risks.

Idaho and Oregon Telehealth Notes

A few practice-policy points worth calling out:

• Location at time of visit matters. You must be physically located in Idaho or Oregon (or another state where I'm licensed — WA, NV, AZ) at the time of the appointment. Traveling out of state? Reschedule.
• Address and pharmacy on file must be current. A prescription sent to the wrong pharmacy or state can require re-issuance and delay your medication.
• Controlled substance history — I check PDMP every visit, not just the first one. If another prescriber is also writing controlled substances for you, we coordinate. Duplicate prescribing is a hard no.
• Rules are not settled. If DEA finalizes the Special Registration framework in 2027, there may be a new set of requirements. I'll notify current patients directly if anything material changes.

Practical Next Step

If you're an adult in Oregon or Idaho who thinks you have ADHD or already has a diagnosis and needs continuity of care:

1. Book an initial evaluation at brandon-kruse.clientsecure.me/request
2. If you have prior records — school evaluations, prior ADHD assessments, prior stimulant prescriptions — gather them for the intake
3. Have a local pharmacy in mind for first-fill of any Schedule II medication

Questions before booking? Send a message through Spruce or email [email protected].

Spruce Message Template

Subject: ADHD telehealth — new patient question

Hi — I live in [Oregon / Idaho] and I'm considering booking an ADHD evaluation. A few questions before I schedule:

• I [do / do not] have a prior ADHD diagnosis
• I [am / am not] currently taking a stimulant or non-stimulant medication
• My preferred pharmacy is: [name, city]
• One specific question: [your question]

I understand this is self-pay ($400 intake, $200 follow-up) and that a superbill is available. Please let me know the next available intake slot.

Thanks.